All News

RheumNow Podcast square

Future Big BiTEs (6.28.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Read Article
LBP,back,man,spine

Low Back Pain? Take a Walk!

d Jack Cush, MD

A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.

Read Article
FDA has approved risankizumab (Skyrizi) to treat adults with moderately to severely active ulcerative colitis (UC), making it the IL-23 inhibitor approved for UC. Approval is based on two large phase 3 clinical trials (COMMAND, INSPIRE) https://t.co/JWX5SBEvT5 https://t.co/MrMFmOyQqa

Links:

Dr. John Cush RheumNow ( View Tweet)
In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/bVYjnBqpaf

Links:

Dr. John Cush RheumNow ( View Tweet)

lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/NUZ3cc4bUx https://t.co/nGP10y3Kuw

Links:

Dr. John Cush RheumNow ( View Tweet)
BiTEs (Bispecific T cell engagers) kill B cells by engaging T cells. IV blinatumomab (CD19xCD3 BiTE) rx of 6 refractory RA pts, led to B & T cell depletion, rapid decline Dz activity, synovitis, autoAbs & was safe, w/ brief temp & ^CrP w/ 1st rx https://t.co/ebLsknirtQ https://t.co/eEIch4g0I1

Links:

Dr. John Cush RheumNow ( View Tweet)
holding hands together support frail

Is Rheumatoid Arthritis Preventable?

d Jonathan Kay, MD

Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis. However, the "Holy Grail" remains the prevention of its development. During a clinical symposium at EULAR 2024 in Vienna, updates were presented on four prospective intervention trials conducted in patients experiencing joint pain without visible joint swelling.

Read Article
FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw

Links:

Dr. John Cush RheumNow ( View Tweet)
Rituximab vs. Tocilizimab for Scleroderma: Which is Better? Dr. Janet Pope discusses abstract OP0295 presented at Eular 2024 in Vienna, Austria. https://t.co/70YF2wxwj5 https://t.co/8BHCafFs3u

Links:

Dr. John Cush RheumNow ( View Tweet)
Rituximab to Treat Systemic Features of Sjogren's Dr. Yuz Yusof discusses abstract OP0076 presented at Eular 2024 in Vienna, Austria. https://t.co/9oJNz12cCI https://t.co/bZxpbf3PT9

Links:

Dr. John Cush RheumNow ( View Tweet)
Update on Sjogren's disease trials With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 RCTs in Sjogren's disease. https://t.co/qMxEX73BsM https://t.co/CQWaAIO4IK

Links:

Dr. John Cush RheumNow ( View Tweet)
New Treatments for Systemic Sclerosis aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed. https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z

Links:

Dr. John Cush RheumNow ( View Tweet)
Camels and psoriatic arthritis - a new treatment link https://t.co/0SQt3UPmKu https://t.co/zvwH9iYtxX

Links:

Dr. John Cush RheumNow ( View Tweet)
We've Got to Talk about CAR T cells Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria. https://t.co/mrr5MWxeJz https://t.co/0FMLaAxaWV

Links:

Dr. John Cush RheumNow ( View Tweet)
Select your GCA Therapy Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria. https://t.co/TPBeU7KaEq https://t.co/09uEzM3Kkd

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @Yuz6Yusof https://t.co/eSqOkBGBK2
Dr. John Cush RheumNow ( View Tweet)
couple holding hands with baby shoes

RA: update for women of child bearing potential (and men!)

d Aurelie Najm, MD, PhD

Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients.

EULAR this year proposed new fertility data, especially in Rheumatoid Arthritis, along with an update of the EULAR points to consider for use of antirheumatic drugs in reproduction, pregnancy and lactation.

Read Article
JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. https://t.co/G96x5UMZOX https://t.co/4cOuIbcHVt

Links:

Dr. John Cush RheumNow ( View Tweet)
eyes

Update on Sjogren's disease trials

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 randomised controlled trials in Sjogren's disease (iscalimab, ianalumab, dazodalibep, and sequential therapy belimumab + rituximab). Since many previous studies have shown the discordance between physician assessment and patient’s symptom burden, there is a glimmer of hope with the efficacy signals demonstrated by both iscalimab and dazodalibep in two patient cohorts; a) cohort 1 = high disease activity with variable symptom burden and b) cohort 2 = high symptom burden but low disease activity. EULAR 2024 offered additional updates.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.